News & Insights #21

This earnings season is still a brilliant one for expanding my watchlist with more absurd-cheap cheap stocks and several promising high-growth stocks that have substantially de-rated

This editions includes;

• Solid 2024H1 results for most of my HK 第部分,

• A pharma stock at c3x P/E that just grew profits 70% and has more growth potential from product launches, and

• Lots more

Links, references & more

• Pinduoduo woke up and chose war; as so often, Chinese/HK investing news was dominated by Big Tech. Once more

  Investing in China
  provided a great analysis, which you can read 👉 here.

  Personally, I am glad I have managed to resist the temptation of buying into Chinese tech. I HAVE been warming up to faster-growth companies.

• Sell everything to save the day; this Caixin 👉 story says that mounting debt pressures and dwindling coffers are forcing Chinese local governments to raise cash. That corresponds with the recent step-up in dividend payouts from SOEs like Tianjin Development.

Founders

The Founders section includes;

• The most-recent Portfolio, yielding 5% with a mix of (absurd-cheap) high-dividend stocks, hidden gems, and odd lots.

  I do still need to update the tables for the Ming Fai exit.

• Index; This is a useful evergreen guide to navigate to key posts and companies on this substack

• Financial analyses; to-date, there are spreadsheets on Yum China, DPC Dash (Domino’s China), the Namibian oil assets for Africa Oil and Sintana Energy, Sylogist, and Tier 1 Technology.

• Several exclusive ideas, such as these two microcaps 👉 here;

  • A European food ingredients company with a high-single digit % dividend yield

  • A North American roll-up story trading at an estimated <6x P/E for 2025